It's all about Ebola. Few know about Inovio. The market is short sighted and does not care about the long term prospects of small pharmaceutical companies.
Does Inovio want to be in the Ebola vaccine business? Maybe for humanity sake, but not for investment sake. The Ebola play, as many traders are focused on these past several weeks, has created volatility in INO and made this a trading stock. When the dust settles, where will Inovio be? Will a vaccine be too late as other drug makers are first to stop the spread? Does Kim really care about Inovio's participation?
Doesn't look so good now...
INO is not an Ebola stock but is lumped together with companies which trade erratically depending on the latest news. It is now a trading stock and investors will tend to stay away. Wrong crowd buying the stock.
Not happening. Too much in the pipeline to not see vaccines developed for commercial use. At least five years away from buyout. Kim is not money hungry--prestige more important.
I would guess Merck. With all of the recent attention, Kim needs to get a deal done while Inovio has mindshare. If not, it will be Roche all over again.
Ok, so what is so compelling about this company? Why own stock?
Michery is running this company into the ground. Everything he touches is mismanaged, delayed or marketed terribly. There is complete lack of transparency, little communication with shareholders.
Watch for lawsuits in the coming weeks and months.
Not likely. Unless there are widespread breakouts in other parts of the country, the Ebola threat will gradually subside. Perhaps that's why Kim ignored the question and talked about Inovio in general terms during the CNBC interview.
I'm thinking way too many penalties that stop drives:
1 Delay of game
2. Pass interference (offensive)
3.Holding (lengthy trials)
4.Block in the back (reverse split)
High of day in first few minutes of trading, then a steady decline. Still looking for a $9.75 close.
Headed to $8....that may be a good entry point for a quick 25% pop and sell at $10.
Let's face it, INO has become a trading stock because long term investors have not bought in to the future viability of the company. Too much talk, too much hype, not enough results, better biotechs elsewhere.
Admittedly, I drank the kool-aid like a lot of folks but now see the light.